Arch Biopartners Stock Fundamentals
| ARCH Stock | CAD 1.77 0.05 2.91% |
Arch Biopartners fundamentals help investors to digest information that contributes to Arch Biopartners' financial success or failures. It also enables traders to predict the movement of Arch Stock. The fundamental analysis module provides a way to measure Arch Biopartners' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arch Biopartners stock.
At this time, Arch Biopartners' Depreciation And Amortization is fairly stable compared to the past year. Total Revenue is likely to climb to about 2.4 M in 2024, despite the fact that Operating Income is likely to grow to (4.5 M). Arch | Select Account or Indicator |
Arch Biopartners Company Shares Outstanding Analysis
Arch Biopartners' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Arch Biopartners Shares Outstanding | 64.94 M |
Most of Arch Biopartners' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arch Biopartners is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Arch Shares Outstanding Driver Correlations
Understanding the fundamental principles of building solid financial models for Arch Biopartners is extremely important. It helps to project a fair market value of Arch Stock properly, considering its historical fundamentals such as Shares Outstanding. Since Arch Biopartners' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arch Biopartners' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arch Biopartners' interrelated accounts and indicators.
Click cells to compare fundamentals
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Arch Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Arch Biopartners has 64.94 M of shares currently outstending. This is 64.03% lower than that of the Biotechnology sector and 39.23% lower than that of the Health Care industry. The shares outstanding for all Canada stocks is 88.64% higher than that of the company.
Arch Biopartners Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arch Biopartners's current stock value. Our valuation model uses many indicators to compare Arch Biopartners value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arch Biopartners competition to find correlations between indicators driving Arch Biopartners's intrinsic value. More Info.Arch Biopartners is number one stock in return on asset category among its peers. It also is number one stock in profit margin category among its peers . At this time, Arch Biopartners' Net Loss is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Arch Biopartners' earnings, one of the primary drivers of an investment's value.Arch Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arch Biopartners' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arch Biopartners could also be used in its relative valuation, which is a method of valuing Arch Biopartners by comparing valuation metrics of similar companies.Arch Biopartners is currently under evaluation in shares outstanding category among its peers.
Arch Biopartners Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arch Biopartners from analyzing Arch Biopartners' financial statements. These drivers represent accounts that assess Arch Biopartners' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arch Biopartners' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 82.1M | 104.9M | 187.1M | 6.8M | 6.1M | 5.8M | |
| Enterprise Value | 84.8M | 109.6M | 191.0M | 8.5M | 7.6M | 7.2M |
Arch Fundamentals
| Return On Asset | -0.81 | ||||
| Profit Margin | (1.86) % | ||||
| Operating Margin | (1.39) % | ||||
| Current Valuation | 119.89 M | ||||
| Shares Outstanding | 64.94 M | ||||
| Shares Owned By Insiders | 19.86 % | ||||
| Number Of Shares Shorted | 3.97 K | ||||
| Price To Sales | 83.08 X | ||||
| Revenue | 1.98 M | ||||
| Gross Profit | (502.88 K) | ||||
| EBITDA | (5.24 M) | ||||
| Net Income | (3.33 M) | ||||
| Cash And Equivalents | 72.82 K | ||||
| Total Debt | 5.02 M | ||||
| Current Ratio | 0.32 X | ||||
| Book Value Per Share | (0.10) X | ||||
| Cash Flow From Operations | (234.07 K) | ||||
| Short Ratio | 0.29 X | ||||
| Earnings Per Share | (0.03) X | ||||
| Beta | 1.39 | ||||
| Market Capitalization | 129.88 M | ||||
| Total Asset | 1.17 M | ||||
| Retained Earnings | (28.05 M) | ||||
| Working Capital | (4.81 M) | ||||
| Net Asset | 1.17 M |
About Arch Biopartners Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arch Biopartners's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arch Biopartners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arch Biopartners based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.3 M | 1.3 M | |
| Total Revenue | 2.3 M | 2.4 M | |
| Cost Of Revenue | 2.4 M | 1.3 M | |
| Stock Based Compensation To Revenue | 1.14 | 1.08 | |
| Sales General And Administrative To Revenue | 0.13 | 0.13 | |
| Research And Ddevelopement To Revenue | 0.88 | 0.84 | |
| Capex To Revenue | 0.07 | 0.06 | |
| Revenue Per Share | 0.13 | 0.14 | |
| Ebit Per Revenue | (0.09) | (0.10) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arch Stock Analysis
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.